Jazz Pharmaceuticals (NASDAQ:JAZZ) Releases FY 2025 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 22.500-24.000 for the period, compared to the consensus estimate of 24.000. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. Jazz Pharmaceuticals also updated its FY 2025 guidance to 22.500-24.000 EPS.

Wall Street Analyst Weigh In

Several research firms recently issued reports on JAZZ. Robert W. Baird increased their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Royal Bank of Canada decreased their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $182.47.

Jazz Pharmaceuticals Stock Down 1.0 %

JAZZ traded down $1.50 during trading on Thursday, reaching $142.67. The stock had a trading volume of 796,368 shares, compared to its average volume of 698,451. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $148.06. The company has a market capitalization of $8.63 billion, a price-to-earnings ratio of 20.15, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock’s 50 day moving average is $125.87 and its two-hundred day moving average is $118.62.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 5,053 shares of company stock valued at $617,442 in the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.